The role of LBP in transduction of signal induced by LPS and in modulation of immune system response;Rola LBP w transdukcji sygnału indukowanego LPS i w modulacji odpowiedzi układu immunologicznego

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 1, 2006, Pages 127-134

  Mierzchała, Magdalena ^a   Lipińska Gediga, Małgorzata ^a   Durek, Grazyna ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Endotoxin; Lipopolysaccharide binding protein; Receptor CD14; Toll like receptors

Indexed keywords

ACUTE PHASE PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PEPTIDOGLYCAN; PROCALCITONIN; TEICHOIC ACID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; BACTERIAL CELL WALL; CELL ACTIVATION; CYTOKINE RELEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION; INJURY; INTENSIVE CARE; NONHUMAN; PATIENT MONITORING; PHAGOCYTE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SURGERY; THERAPY EFFECT;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 33645313481     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Van Amersfoort ES, Van Berkel TJ, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003, 16, 379-414.
2. Fischer W: Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus. Med Microbiol Immunol 1994, 183, 61-76.
3. Fischer W, Koch HU: Alanyl lipoteichoic acid of Staphylococcus aureus: functional and dynamic aspects. Biochem Soc Trans 1985, 13, 984-986.
4. Rose RK, Hogg SD: Competitive binding of calcium and magnesium to streptococcal lipoteichoic acid. Biochim Biophys Acta 1995, 1245, 94-98.
5. Navarre WW, Schneewind O: Surface proteins of gram-positive bacteria and mechanism of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 1999, 63, 174-229.
6. Giesbrecht P, Kersten T, Maidhof H, Wecke J: Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicilin. Microbiol Mol Biol Rev 1998, 62, 1371-1414.
7. Frank MM, Fries LS: The role of complement in inflammation and phagocytosis. Immunol Today 1991, 12, 322-331.
8. Kirschning CJ, Unbehaun A, Fiedler G, Hallatschek W, Lamping N, Pfeil D, Schumann RR: The Transcriptional Activation Pattern of Lipopolysaccharide Binding Protein (LBP) Involving Transcription Factors AP-1 and C/EBPβ. Immunobiol 1997, 198, 124-135.
9. Schumann RR, Leong SR, Flaggs GW, Gray GW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 1990, 249, 1429-1431.
10. Schumann RR, Zweigner J: A novel acute- phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 1999, 37, 271-274.
11. Triantafilou M, Triantafilou K: Lipopolysaccharide recognition: CD14, TRLs and the LPS-activation cluster. Trends Immunol 2002, 23, 301-304.
12. Ulevitch RJ, Tobias PS: Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999, 11, 19-22.
13. Ramadori G, Meyer zum Buschenfelde KH, Tobias PS, Mathison JC, Ulevitch RJ: Biosynthesis of lipopolysaccharide - binding protein in rabbit hepatocytes. Pathobiology 1990, 58, 89-94.
14. Vreugdenhil AC, Dentener AM, Snoek AM, Greve JV, Buurman WA: Lipopolysaccharide - binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 1999, 163, 2792-2798.
15. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR: High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001, 13, 3800-3808.
16. Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR: Organization of the human cholesteryl ester transfer protein gene. Biochemistry 1990, 29, 1372-1376.
17. Kirschning CJ, Au-Young J, Lamping N, Reuter D, Pfeil D, Seilhamer J, Schumann RR: Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins. Genomics 1997, 46, 416-425.
18. Tobias PS, Mathison JC, Ulevitch RJ: A family of lipopolysaccharide - binding proteins involve in responses to gram-negative sepsis. J Biol Chem 1988, 263, 13479-13481.
19. Tobias PS, Mathison JC, Mintz D, Lee JD, Kravchenko V, Kato K, Pugin J, Ulevitch RJ: Participation of lipopolisaccharide binding protein in lipopolysaccharide-dependent macrophage activation. Am. J Respir. Cell Mol Biol 1992, 7 239-245.
20. Kirschning CJ, Unbehaun A, Lamping N, Pfeil D, Herrmann F, Schumann RR: Control of transcriptional activation of the lipopolysaccharide-binding protein (LBP) gene by proinflammatory cytokines. Cytokines Cell Mol Ther 1997, 3, 59-62.
21. Schumann RR, Latz E: Lipopolysaccharide-binding protein. Chem Immunol 2000, 74, 42-60.
22. Tall AR, Forester LR, Bongivanni GL: Facilitation of phosphatidylcholine transfer into high density lipoproteins by an apolipoprotein in the 1.20-1.26 g/ml fraction of plasma. J Lipid Res, 1983, 24, 277-289.
23. Ulevitch RJ, Johnston AR: The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Investig 1978, 62, 1313-1324.
24. Ulevitch RJ, Johnston AR, Weinstein DB: New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Investig 1981, 67, 827-837.
25. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA: The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986, 83, 2704-2708.
26. Netea MG, Demacker PN, Kullberg BJ, Jacobs LE, Verver-Jansen T, Boerman OC, Stalenhoef AF, Van der Meer JW: Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine 1998, 10, 766-772.
27. Lamping N, Dettmer R, Schroeder NWJ, Pfeil D, Hallatscheck W, Burger R, Schumann RR: LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Investig 1998, 101, 2065-2071.
28. White ML, Ma JK, Mendoza NT, Dedrick RL, Carroll SF: Differential acute phase response between subjects with inflammatory, infectious and non-infectious disease. Abstracts of the 35th ICAAC 1995, 77.
29. Froon AHM, Dentener MA, Willem J, Greve M, Ramsay G, Buurman WA: Lipopolysaccharide toxicity-regulating proteins in bacteriemia. J Infect Dis 1995, 171, 1250-1257.
30. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect. Dis 1999, 180, 1584-1589.
31. Blairon L, Wittebole X, Laterre PF: Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to Gram-positive and fungal infections. J Infect Dis 2003, 187, 287-291.
32. Kaden J, Zwerenz P, Lambrecht HG, Dostatni R: Lipopolysaccharide-binding protein as a new and reliable infection marker after kidney transplantation. Transpl Int 2002, 15, 163-172.
33. Orlikowsky T, Schumacher C, Deperschmidt N, Henkel C, Niethammer D, Goetz R: Lipopolysaccharid (LPS)-bindendes Protein (LBP) im Plasma von gesunden Neugeborenen und Neugeborenen mit neonataler bakterieller Infektion. Z Geburtshilfe Neonatol 2001, 205 (Suppl. 1): S26-S27.
34. Yu B, Wright SD: Catalytic properties of lipopolysaccharide (LPS) binding protein (LBP): Transfer of LPS to soluble CD14. J Biol Chem 1996, 271, 4100-4105.
35. Gutsmann T, Müller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U: Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001, 69, 6942-6950.
36. Pruchal M, Herold I, Zazula R, Dubska L, Dostal M, Hildebrand T, Hyanek J: Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Critical Care 2003, 7, R154-R159.
37. Tobias PS, Soldau K, Ulevitch RJ: Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide-binding protein. J Biol Chem 1989, 264, 10867-10871.
38. Tobias PS, Soldau K, Ulevitch RJ: Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986, 164, 777-793.
39. Morrison DC, Ryan LJ: Endotoxins and disease mechanisms. Ann Rev Med 1987, 38, 417-432.
40. Rietschel ET, Brade H, Brade L, Brandenburg K, Schade U, Seydel U, Zahringer U, Galanos C, Luderitz O, Westphal O: Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. Prog Clin Biol Res 1987, 231, 25-53.
41. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249, 1431-1433.
42. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS: Toll-like receptor 4, but not Toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000, 165, 5780-5787.
43. Berner R, Fürll B, Stelter F, Dröse J, Müller H-P, Schütt C: Elevated Levels of Lipopolysaccharide Binding Protein and Soluble CD14 in Plasma in Neonatal Early-Onset Sepsis. Clin Diag Lab Immun 2002, 9, 440-445.
44. Wright SD: CD14 and immune response to lipopolysaccharide. Science (Wash. DC), 1991, 252, 1321-1322.
45. Schröder NW, Heine H, Alexander C, Manukyan M, Eckert J, Hamann L, Göbel UB, Schumann RR: Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immun 2004, 173, 2683-2691.
46. Weber JR, Freyer D, Alexander C, Schroder NWJ, Reiss A, Kuster C, Pfeil D, Tuomanen E, Schumann RR: Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 2003, 19, 269-279.
47. Horwitz AH, Williams RE, Nowakowski G: Human lipopolysaccharide-binding protein potentiates bactericidal activity of human bactericidal/ permeability-increasing protein. Infect Immun 1995, 63, 522-527.
48. Wright SD, Tobias PS, Ulevitch RJ, Ramos RA: Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by novel receptor on macrophages. J Exp Med 1989, 170, 1231-1241.
49. White ML, Ma JK, Birr CA, Trown PW, Carroll SF: Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA. J Immunol Methods 1994, 167, 227-236.
50. Martin TR, Mathison JC, Tobias PS, Leturcq DJ, Moriarty AM, Maunder RJ, Ulevitch RJ: Lipopolysaccharide binding protein enhances the reponsiveness of alveolar macrophages to bacterial lipopolysaccharide. J Clin Invest 1992, 90, 2209-2219.
51. Pavcnik-Arnol M, Hojker S, Derganc M: Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6 and C-reactive protein. Intensive Care Med 2004, 30, 1454-1460.